Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

990
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
990
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.1K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

914
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
914
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

1.6K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.2K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with treatment-emergent headache occurrence following RTMS to non-motor areas and the impact on treatment outcomes: a retrospective study.

Frontiers in psychiatry·2026
Same author

The relationship between individual alpha-band activity and cognitive outcomes from repetitive Transcranial Magnetic Stimulation (rTMS) treatment for Major Depressive Disorder (MDD).

Journal of affective disorders·2026
Same author

Efficacy of 5 × 5 accelerated versus conventional repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant depression.

Journal of affective disorders·2026
Same author

Differential neural responses to rhythmic and patterned TMS protocols: Insights from EEG spectral analysis.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Clinical Manifestations.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025
Same author

Biomarkers.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2025

Related Experiment Video

Updated: Jan 29, 2026

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
08:29

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

16.7K

Neuromodulation for Treatment-Refractory PTSD.

Jean-Philippe Langevin1, Ralph J Koek1, Holly N Schwartz1

  • 1is a neurosurgeon, is a neurologist, is a radiologist, and is a neurophysiologist in the research and development service; and are mental/behavioral health physicians, is a psychologist, and is a mental/behavioral health physician in the psychiatry and mental health service; all at the VA Greater Los Angeles Healthcare System in California. Dr. Langevin, Dr. Koek, Dr. Chen, Dr. Sultzer, Dr. Mandelkern, and Dr. Krahl are professors at David Geffen School of Medicine at the University of California Los Angeles.

Federal Practitioner : for the Health Care Professionals of the VA, Dod, and PHS
|February 16, 2019
PubMed
Summary

Deep brain stimulation (DBS) is now showing promise in reducing post-traumatic stress disorder (PTSD) symptoms. This early trial suggests DBS may be a viable treatment for PTSD, building on its success in other neurological conditions.

More Related Videos

Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice
03:26

Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice

Published on: August 1, 2025

748
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.8K

Related Experiment Videos

Last Updated: Jan 29, 2026

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD
08:29

Biomarkers in an Animal Model for Revealing Neural, Hematologic, and Behavioral Correlates of PTSD

Published on: October 10, 2012

16.7K
Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice
03:26

Fixation of Ultrasound Transducers for Spinal Cord Neuromodulation in Mice

Published on: August 1, 2025

748
MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor
05:54

MRI-guided Focused Ultrasound Thalamotomy for Patients with Medically-refractory Essential Tremor

Published on: December 13, 2017

14.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Medical Technology

Background:

  • Deep brain stimulation (DBS) is an established treatment for Parkinson disease and essential tremor.
  • Post-traumatic stress disorder (PTSD) is a debilitating psychiatric condition with limited effective treatments.

Purpose of the Study:

  • To evaluate the safety and preliminary efficacy of DBS in reducing PTSD symptoms.
  • To explore a novel therapeutic approach for treatment-resistant PTSD.

Main Methods:

  • An early-phase safety trial was conducted.
  • Deep brain stimulation was applied to the target patient.

Main Results:

  • The first patient enrolled in the trial showed a reduction in PTSD symptoms.
  • The intervention was tolerated by the patient.

Conclusions:

  • Deep brain stimulation demonstrates potential as a novel treatment for PTSD.
  • Further research is warranted to confirm these preliminary findings in larger trials.